论文部分内容阅读
目的研究分析硼替佐米联合地塞米松方案治疗初治多发性骨髓瘤的临床治疗效果。方法选取我院于2009年4月~2013年1月收治的78例初治多发性骨髓瘤患者,将其按照治疗方法划分,其中对照组41例患者采用长春新碱联合比柔吡星、地塞米松、马法兰治疗,治疗组37例患者采用硼替佐米联合地塞米松方案实施治疗,对比两组患者临床治疗效果。结果两组患者实施治疗后,治疗组总有效率为91.9%,对照组总有效率为78.0%,两组对比,治疗组显著优于对照组,差异有统计学意义(P<0.05)。结论采用硼替佐米联合地塞米松治疗初治多发性骨髓瘤效果显著,可明显改善患者临床症状,值得在临床医学中推广。
Objective To study the clinical efficacy of bortezomib plus dexamethasone in the treatment of newly diagnosed multiple myeloma. Methods 78 patients with newly diagnosed multiple myeloma treated in our hospital from April 2009 to January 2013 were divided according to the method of treatment. Among them, 41 patients in the control group were treated with vincristine combined with doxepin, Semyonis, melphalan treatment group, 37 patients treated with bortezomib plus dexamethasone program implementation of treatment, the clinical efficacy of the two groups were compared. Results After two groups of patients were treated, the total effective rate was 91.9% in the treatment group and 78.0% in the control group. The two groups were significantly better than the control group (P <0.05). Conclusion Bortezomib combined with dexamethasone is effective in treating newly diagnosed multiple myeloma. It can significantly improve the clinical symptoms and is worth popularizing in clinical medicine.